Marc Appel

Marc Appel is an experienced healthcare company builder, investor and operator.

He founded Orange Grove Bio, a biotech platform focused on the investment and development of high caliber drug programs coming out of academic research institutions. Under his leadership, Orange Grove raised significant sums of capital, partnered with over 70 research institutions, and built multiple pharma collaborations. He also personally led multiple innovative operating companies with a focus on autoimmune and inflammatory diseases.

Previously, he helped to build the structured healthcare and royalty investing strategy at Marathon Asset Management, where he was instrumental on a range of large biotech deals. Prior to that, he invested across the capital structure in public market healthcare opportunities. Investments included companies in the specialty pharma, hospital, outpatient services, drug distribution, and biotech sectors. He also has extensive experience in work-out situations, where he restructured companies across a number of different industries.

Marc additionally serves as a financial and legal advisor to physician practices in areas such as business process optimization, billing best practices, and deal negotiation. He has previously held roles at Highbridge Principal Strategies, Eaton Vance, and Kirkland & Ellis. He began his career as an analyst at McKinsey & Co. serving a mix of financial services and healthcare clients.

Marc received his BA from Yale University, summa cum laude, his JD from Harvard Law School, and his MBA from Harvard Business School.